Harrison and Feldhausen

Located in Olney, MD, Harrison and Feldhausen operates within the MD regulatory framework as a licensed addiction-treatment provider. The facility's programming is outpatient (Outpatient, Dual Dx), not residential. Structural evaluation of this facility's clinical posture requires review of state licensing records, accreditation status, and payer-network contracts.

Care levels at Harrison and Feldhausen

Harrison and Feldhausen is an outpatient-focused program (Outpatient, Dual Dx) — patients live at home or in sober living and attend treatment sessions. This level of care is clinically appropriate for mild-to-moderate substance use disorder, or for patients stepping down from residential. ASAM Criteria 4e level-of-care matching requires clinical assessment across six dimensions (withdrawal potential, biomedical conditions, emotional/behavioral/cognitive conditions, readiness, relapse risk, recovery environment). The alignment of Harrison and Feldhausen's offerings to any specific patient's clinical profile should be determined by an independent ASAM-aligned assessment prior to admission.

Insurance and payment

Payment and insurance posture: Harrison and Feldhausen operates primarily on commercial insurance. The implication for patients: higher typical cost-share, potentially more intensive programming, and the full burden of MHPAEA parity-rule dynamics — including appeal rights when the plan denies. Pre-admission Verification of Benefits (VOB) documentation should include: specific plan product and network status, deductible status at time of admission, coinsurance rate applicable, prior authorization status and turnaround, and out-of-pocket accumulation. Under MHPAEA 2024 disclosure rules, plan-specific medical-necessity criteria must be available on request.

Before you call

Pre-admission due-diligence for Harrison and Feldhausen: (1) ASAM 4e level-of-care documentation matching clinical assessment; (2) written Verification of Benefits specific to insurance product; (3) MAT policy documentation (particularly buprenorphine and methadone continuation protocols for opioid use disorder patients); (4) accreditation verification via CARF or Joint Commission provider-search tools; (5) state licensing status confirmed via MD behavioral-health regulator inspection records. If the clinical situation involves opioid use disorder, confirm explicitly whether Harrison and Feldhausen offers medication-assisted treatment — buprenorphine, methadone, or naltrexone. Programs that do not are operating outside the current standard of care.